Latest Pharma and Biotech News
Pharmaceutical
4 April 2025 A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced.
Today's issue
Refine Search
Pharmaceutical
A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced. 4 April 2025
Pharmaceutical
US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of Irish contract manufacturer Zenith Adhesive Components, adding further technical capabilities and boosting regional reach. 4 April 2025
Pharmaceutical
Swedish biotech OncoZenge has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge (bupivacaine), a non-opioid treatment for oral pain caused by cancer therapies. 4 April 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today announced the appointment of Sanjay Keswani to the company's executive management team as chief medical officer (CMO) effective June 2, 2025. 4 April 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wainzua (eplontersen) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), which is a rare progressive condition that runs in families caused by a protein called transthyretin (TTR). 4 April 2025
Pharmaceutical
US biotech Aldeyra Therapeutics has received a Complete Response Letter from the US Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of its dry eye disease candidate reproxalap. 4 April 2025
Pharmaceutical
US pharma major Eli Lilly’s brand value has surged by 108% since entering the weight loss market in 2023, according to a new report from Brand Finance. 3 April 2025
Pharmaceutical
Colorado, USA-based Edgewise Therapeutics, a muscle disease-focused biopharma company, closed 23% lower after Wednesday’s trading. 3 April 2025
Pharmaceutical
With two new lawsuits, Eli Lilly has escalated its legal campaign against the makers of unauthorized versions of its diabetes and weight-loss drugs, Mounjaro (tirzepatide) and Zepbound (tirzepatide), challenging inroads made by drug compounders in what has become a highly lucrative market. 3 April 2025
Pharmaceutical
Pharmaceuticals will be exempt from the tariffs on imports to the USA that were announced by US President Donald Trump Wednesday, according to a White House fact sheet. 3 April 2025
Pharmaceutical
Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. 3 April 2025
Pharmaceutical
CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol in major depressive disorder (MDD) with and without severe excessive daytime sleepiness (EDS). 3 April 2025
Pharmaceutical
The American Gastroenterological Association (AGA) has recently released a major update to its clinical guideline for the pharmacological management of moderate-to-severe ulcerative colitis (UC). 2 April 2025
Pharmaceutical
Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt Pharmaceuticals and Endo, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 2 April 2025
Pharmaceutical
Boehringer Ingelheim, now Germany's largest pharma company, today reported a currency-adjusted 6.1% gain in full-year 2024 revenues, buoyed by its diabetes and lung drugs. 2 April 2025
Pharmaceutical
Freed from their former obligations to remain loyal to agency and state, a number of high-profile figures from the US Food and Drug Administration (FDA) have sounded the alarm about its direction of travel under Robert Francis Kennedy Jr (RFK Jr), the new Secretary of Health and Human Services. 2 April 2025
Pharmaceutical
French drugmaker Sanofi has appointed Chris Corsico as its new global head of development, according to an internal company communication obtained by The Pharma Letter. 2 April 2025
Pharmaceutical
Danish biotech Gubra saw its share gains more than 8% to 448.00 kroner, after it announced positive results from the single ascending dose (SAD) Phase I clinical trial with the long-acting amylin analogue GUBamy (GUB014295). 2 April 2025
Pharmaceutical
UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, untreated Parkinson’s disease, that failed to meet the primary endpoint of the study. 2 April 2025
Pharmaceutical
Japanese drugmaker Sumitomo Pharma said yesterday that it is divesting its Asian business to major Japanese trading house Marubeni for roughly 72 billion yen ($480 million) in a deal that forms part of its post-Latuda (lurasidone) turnaround efforts. 2 April 2025
All news
Pharmaceutical
Seattle, USA-based biotech Curevo Vaccine, which is developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles. 18 March 2025
Pharmaceutical
Scottish gut health specialist EnteroBiotix has announced positive initial results with EBX-102-02, its full-spectrum microbiome product, from the TrIuMPH Phase IIa trial in adults with irritable bowel syndrome with constipation (IBS-C). 18 March 2025
Pharmaceutical
The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone) in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%, ie, mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). 18 March 2025
Pharmaceutical
US biotech OPKO Health and Israeli firm Entera Bio ave entered into a collaboration to develop an oral GLP-1/glucagon dual agonist tablet for obesity, metabolic conditions, and fibrotic diseases. 18 March 2025
Pharmaceutical
We live in a world where technology is playing an increasingly significant role in our daily lives. In the biopharmaceutical industry, using artificial intelligence (AI) as a tool can help improve efficiency, discover new cures and treatments and enhance clinical trials. 18 March 2025
Pharmaceutical
Precision medicine has advanced significantly over the past decade, driven by breakthroughs in chemical, hardware, software, and especially cloud computing technologies. 18 March 2025
Pharmaceutical
Hours after the swearing-in of the Secretary of Health and Human Services, Robert F Kennedy Jr (RFK), President Donald Trump issued an executive order establishing the Make America Healthy Again Commission (MAHA). 17 March 2025
Pharmaceutical
Abalone Bio, an antibody company measuring large-scale activity data to drive AI-powered discovery of active therapeutics, has announced a collaboration with the University of Pennsylvania, Perelman School of Medicine, to develop new antibody-based obesity drugs. 17 March 2025
Pharmaceutical
Sales of antidepressants in Russia during the period of January-February 2025 amounted to 2.8 billion roubles ($30 million) with a total of 3.2 million packages sold, which became a record figure for the country in the last five years, reports The Pharma Letter’s local correspondent. 17 March 2025
Pharmaceutical
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical significance in adults with chronic hypoparathyroidism (HypoPT) at 24 weeks, compared to placebo 17 March 2025
Pharmaceutical
The Roche subsidiary Genentech has presented five-year SUNFISH data on Evrysdi (risdiplam) in the final readout of this pivotal study. 17 March 2025
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca and Korean biotech Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase using Hybrozyme platform technology. 17 March 2025
Pharmaceutical
Spanish plasma-derived medicines specialist Grifols has announced positive results from its Phase II/III clinical trial evaluating the efficacy and safety of its intravenous immunoglobulin (IVIG) to treat patients with post-polio syndrome (PPS), demonstrating a significant improvement in distance walked compared to placebo. 17 March 2025
Pharmaceutical
Fourteen public and private parties, including pharmaceutical companies Astellas and Merck KGaA, have developed a drug for a 'forgotten' tropical disease: schistosomiasis. This is a serious worm infection that mainly occurs in Africa and South America. 17 March 2025
Pharmaceutical
Chinese pharmaceutical company Fosun Pharmaceutical Group has agreed to sell its stake in private hospital operator United Family Healthcare to an investment firm owned by US private equity giant Warburg Pincus. 14 March 2025
Pharmaceutical
Guaranteed success in drug development does not exist, such are the inherent risks, potential pitfalls and costs involved. But UK-based Ellipses Pharma has developed a model that - if its founder’s convictions prove accurate - will maximize the probability of success and lead to a host of new oncology drugs being brought to market by big pharma. 14 March 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has announced its recommendations to vaccine manufacturers for the virus strains to be used in influenza (flu) vaccines for the 2025-2026 US flu season following a thorough and comprehensive review of US and global surveillance data. 14 March 2025
Pharmaceutical
The UK has announced plans to abolish NHS England and integrate its functions into the central government, marking a significant shift in the nation's healthcare management. The restructuring aims to cut bureaucracy and enhance efficiency, resulting in approximately 10,000 job losses, with the anticipated savings redirected to frontline services. 14 March 2025
Pharmaceutical
The UK government plans to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies' National Health Service (NHS) sales in the second half of 2025. 14 March 2025
Pharmaceutical
USA-based Azurity Pharmaceuticals says it has completed its acquisition of Covis Group from existing investors and the privately-held Swiss drugmaker is now a wholly-owned subsidiary of Azurity. 14 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze